Oral COS administration was found to protect the mice from DSS-induced colitis by suppressing the production of inflammatory factors, preventing the inflammation response via activating PPARγ and SIRT1, inhibiting the acetylation and phosphorylation of NF-κB p65, and optimizing the intestinal microbiota composition. Here, NFKB1 is linked to colitis.